Jung et al. 36 (PMID 26212545) observed that sugiol, an anti‐tumour compound for prostate cancer, increases ROS levels, leading to activation of ERK and subsequent inhibits STAT3 activity. This evidence concerns the gene STAT3 and prostate carcinoma.